We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Eurofins Technologies

Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test k... read more Featured Products: More products

Download Mobile App





Ground-Breaking and Novel Assays to Help Assess Organ and Tissue Damage in Transplant and COVID-19 Patients

By LabMedica International staff writers
Posted on 22 Mar 2022

A new collaboration will expand access to blood and urine-based cell-free DNA detection methods that will provide healthcare practitioners with highly accurate, non-invasive tools to identify and monitor for infection, rejection, and severity of organ damage in transplant and COVID-19 patients.

Eurofins Viracor, LLC (Lees Summit, MO, USA) has entered into an exclusive license agreement with Cornell University (Ithaca, NY, USA) to commercialize several ground-breaking and novel assays aimed at transforming the clinical management of COVID-19 and transplant patients impacted from tissue damage and infections. Surgical biopsy is critical in tracking damage of COVID-19 in the body, but the procedure can be painful and costly to the patient. Researchers at Cornell have developed an alternative to biopsy – a novel, noninvasive blood test to measure organ injury from COVID-19. The test uses circulating cell-free DNA (cfDNA) to gauge the damage that COVID-19 inflicts on cells, tissues and organs.

Additionally, cfDNA is a highly versatile analyte for monitoring the most critical complications of hematopoietic cell transplantation (HCT) for many blood disorders and cancers, including Graft-Versus-Host Disease, infection, graft failure and disease relapse. The agreement between Eurofins and Cornell will expand access to an innovative blood-based cfDNA methylation sequencing assay for early detection or prediction of major complications related to allogeneic HCT, thus improving the care of stem cell transplant patients. In another application, Eurofins intends to commercialize the novel cfDNA test used to identify the presence of urinary tract infections in kidney transplant patients and quantify the degree of damage to the kidney and bladder.

Related Links:
Eurofins Viracor, LLC
Cornell University 

Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
New
3-Position Stirrer
ST-200 and SHP-200 Series
New
Dehydroepiandrosterone Assay
DHEA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The DNA sequencing method indentifies the bacterial causes of infections to determine the most effective antibiotics for treatment (Photo courtesy of Shutterstock)

New DNA Test Diagnoses Bacterial Infections Faster and More Accurately

Antimicrobial resistance has emerged as a significant global health threat, causing at least one million deaths annually since 1990. The Global Research on Antimicrobial Resistance (GRAM) Project warns... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.